This inventor holds 1 USPTO granted patent and 7 published patent applications. Top assignee: Novartis Ag. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Astrid Jullion: Innovator in Cancer Treatment
Introduction
Astrid Jullion is a prominent inventor based in Sierentz, France. She has made significant contributions to the field of cancer treatment through her innovative research and development of pharmaceuticals. Her work focuses on the interaction between HDM2 and p53, which plays a crucial role in cancer biology.
Latest Patents
Astrid Jullion holds a patent for a groundbreaking invention titled "Dose and regimen for HDM2-p53 interaction inhibitors." This invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer. The drug is administered using a high-dose intermittent dosing regimen. Specifically, her invention pertains to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4-week cycle. She has 1 patent to her name.
Career Highlights
Astrid Jullion is associated with Novartis AG, a leading global healthcare company. Her work at Novartis has allowed her to collaborate with other talented professionals in the field. She has made strides in developing effective treatments that target cancer at its core.
Collaborations
Throughout her career, Astrid has worked alongside notable colleagues such as Stephane Ferretti and Sebastien Jeay. These collaborations have enhanced her research and contributed to the advancement of cancer therapies.
Conclusion
Astrid Jullion is a dedicated inventor whose work in cancer treatment is paving the way for innovative therapies. Her contributions to the field are invaluable, and her patent reflects her commitment to improving patient outcomes.